Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Appointment of Utpal Koppikar as Chief Financial Officer
On June 7, 2018, Atara Biotherapeutics, Inc. (“Atara” or the “Company”) announced the appointment of Utpal Koppikar as Chief Financial Officer.
Mr. Koppikar, age 47, was with Gilead Sciences, Inc. from June 2011 until June 2018 where he was most recently VP, Corporate and Operations Finance. Mr. Koppikar also previously served as Vice President of EMEA Finance and Senior Director Commercial Finance at Gilead Sciences, Inc.Prior to that, Mr. Koppikar held multiple roles at Amgen Inc. from January 2001 to June 2011.Mr. Koppikar has a BS from the University of Maryland, an MS from Stanford University and an MBA from the UCLA Anderson School of Management.
Mr. Koppikar will receive an annual salary of $425,000, a sign-on bonus of $100,000 and will have a bonus target equal to 35% of his base salary, to be paid upon achievement of certain corporate goals.In addition, Mr. Koppikar will receive 75,000 stock options and 45,000 restricted stock units.
Mr. Koppikar has no family relationships with any director, executive officer or person nominated or chosen by Atara to become a director or executive officer of Atara.Mr. Koppikar is not a party to any transaction required to be disclosed to Item 404(a) of Regulation S-K.
About Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics. Its T-cell product candidates include Epstein Barr Virus-cytotoxic T lymphocytes (EBV-CTL), which is in Phase II clinical trials for malignancies associated with EBV; cytomegalovirus (CMV)-CTL, which is in Phase II clinical trials for CMV, and Wilms Tumor 1 (WT1)-CTL, which targets cancers expressing the antigen WT1. Its molecularly targeted product candidates include STM 434, which is in Phase I clinical trial of STM 434 for ovarian cancer and other solid tumors; ATA 777, a fully human antibody targeting Activin A; ATA M43, a fully human anti-Actin-related protein 2-A (ActR2A)/2B monoclonal antibody; STM 217; ActR2B5, and ATA 842, a humanized antibody targeting myostatin.